HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN)

Key Points

• HC Wainwright has lowered its Q3 2025 earnings estimate for Arvinas, now forecasting a loss of ($0.82) per share, down from a prior estimate of ($0.53), while maintaining a "Buy" rating and a price target of $18.00.
• Arvinas reported a revenue of $22.40 million for the last quarter, significantly below analyst expectations of $34.42 million, reflecting a 70.7% year-over-year decline in revenue.
• While the stock has had a consensus rating of "Moderate Buy," recent evaluations saw Citigroup, Leerink Partners, and BMO Capital Markets adjusting their price targets downward, indicating a cautious outlook from analysts.

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Arvinas in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior forecast of ($0.53). HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at $1.83 EPS and FY2029 earnings at $0.89 EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The company had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. During the same period in the previous year, the business earned ($0.49) EPS. The firm's revenue for the quarter was down 70.7% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the stock. Citigroup cut their target price on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research report on Monday, May 5th. Leerink Partnrs downgraded shares of Arvinas from a "strong-buy" rating to a "hold" rating in a research report on Sunday, June 1st. Wells Fargo & Company cut their target price on shares of Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Thursday. BMO Capital Markets cut their price objective on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research report on Monday, May 5th. Finally, BTIG Research set a $16.00 price objective on shares of Arvinas and gave the company a "buy" rating in a research report on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.76.

Arvinas Stock Up 0.8%

Shares of NASDAQ ARVN opened at $6.29 on Monday. Arvinas has a twelve month low of $5.90 and a twelve month high of $29.61. The firm has a market cap of $461.81 million, a P/E ratio of -6.23 and a beta of 2.22. The company has a 50 day moving average of $7.52 and a 200 day moving average of $9.86.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Arvinas by 18.4% in the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after buying an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after purchasing an additional 249,295 shares in the last quarter. RTW Investments LP lifted its stake in Arvinas by 19.8% in the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Arvinas in the 4th quarter worth $42,332,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Arvinas in the 1st quarter worth $12,636,000. Institutional investors own 95.19% of the company's stock.

Insiders Place Their Bets

In related news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total value of $43,377.00. Following the completion of the transaction, the chief financial officer owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.73% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.